Document:

EX-4.3

 Exhibit 4.3 
  

					
	  
  
  

 
  
 Private &
Confidential
 Alan Jope
 alan.jope@unilever.com
	  	 

  
	  	

 20 February 2020 
 Dear Alan 

Your reward package in respect of 2020 
 This letter outlines your
reward package for 2020 authorised by the Compensation Committee (the “Committee”). Any defined terms used have the meaning set out in your service agreement (your “Agreement”) with Unilever PLC and Unilever NV (collectively
referred to here as “Unilever”) if not otherwise defined here. 
  

			
	REWARD PACKAGE FOR 2020 
		
	Fixed pay:	  	 1,508,000 EUR p.a.
  

With effect from 1 January 2020, your fixed pay has been reviewed by the Compensation Committee and has increased by 4%. Your fixed pay is denominated in Euros (and
payable in equal monthly instalments).

		
	Discretionary annual bonus:	  	 2019: Discretionary annual bonus outcome: 1,783,500 EUR
  

This is your annual bonus award in respect of 2019. It represents your annual bonus target (150% of your fixed pay) multiplied by Unilever’s 2019 performance ratio
of 82%. Any cash portion of your bonus payable to you (less MCIP election – see below) will be paid in the March 2020 payroll. For further details regarding your bonus outcome, please refer to the Directors’ Remuneration Report (DRR) of
the 2019 Annual Report and Accounts (ARA).
  
 2020: Discretionary annual bonus target: 150% of
fixed pay
  
 Your discretionary annual bonus target for 2020 is set out above. The maximum
discretionary annual bonus is 225% of fixed pay (150% of target bonus). Performance measures are as set out in the Directors’ Remuneration Report (DRR) of the 2019 Annual Report and Accounts (ARA). Details of the performance targets approved by
the Committee will be communicated to you separately.

		
	MCIP:	  	 2019: You have chosen to invest 1,194,945 EUR in the MCIP 2020-2023
  

You have opted to invest the maximum 67% (1,194,945 EUR) of your 2019 discretionary annual bonus award in Unilever shares (“investment shares”) under the
Unilever Share Plan 2017 (the “Plan”). Each of these investment shares will become eligible for 1.5 match shares which will vest between 0-200% four years from the award date in line with the rules
of the Plan and performance against the measures/targets set out in the DRR.
  
 An additional one-year holding period will apply after the four-year vesting period.

		
	Benefits:	  	 Unilever will provide the following benefits as set out below:
  

•  medical cover for you and your family via the Allianz Worldwide Care International Healthcare
Plan;
  
 •  life insurance cover
at three times your fixed pay; and
  

•  actual and reasonable costs of tax return preparation in respect of total Unilever earnings via
Unilever’s designated tax advisor.

 Please note that, whilst performance measures and target ranges have been approved by the Committee,
in-flight performance measures and target ranges may be adjusted if and to the extent deemed appropriate by the Committee (in which case we will notify you separately in writing). 

In addition, all 2020 payments/awards set out above (including MCIP 2020-2023 Match shares) are gross, and subject to: any necessary deductions for tax/social security;
the malus/clawback provisions set out below; the 

 
terms and conditions of your Agreement (which are unchanged save as set out in this letter), relevant award documentation, plan rules and related policies/standards (as amended or replaced from
time to time) 
 Malus and clawback. All performance-related remuneration awarded to you, including but not limited to any annual bonus and GSIP/
MCIP awards, is subject to malus and clawback as follows: 
 Malus: If the Committee considers that there is: 

 

	 	•	 	 a significant downward restatement of the financial results of Unilever; 

 

	 	•	 	 reasonable evidence of gross misconduct or gross negligence by you; 

 

	 	•	 	 reasonable evidence of material breach by you of Unilever’s Code of Business Principles or Code Policies;

  

	 	•	 	 breach of restrictive covenants by which the individual has agreed to be bound; and/or 

 

	 	•	 	 reasonable evidence of conduct by you that results in significant losses or reputational damage to Unilever,

 it may, in its discretion, at any time prior to your performance-related remuneration vesting or being paid, decide that some or all of your
performance-related remuneration (which is subject to this malus and clawback provision) will be reduced, lapse, or be subject to additional conditions, or the delivery of your performance-related remuneration will be delayed. 

Clawback: If the Committee considers that there is a significant downward restatement of our financial results it may, in its discretion, within two years of
your performance-related remuneration (which, for the avoidance of doubt) includes vested awards under the GSIP and MCIP) vesting or being paid: 
  

	 	•	 	 require you to repay to Unilever (or as Unilever directs) an amount equal to the
after-tax value of some or all of any cash bonus you were paid (as determined by the Committee); and/or 

  

	 	•	 	 require you to transfer to Unilever (or as Unilever directs) for nil consideration, some or all of the after-tax number of Unilever shares which have previously vested, or pay to Unilever (or as Unilever directs) an amount equal to the value of those shares (as determined by the Committee); and/or

  

	 	•	 	 require Unilever to withhold from, or offset against, any other remuneration to which you may be or become entitled in
connection with your employment such an amount as the Committee considers appropriate. 

 Where you are notified that you must transfer shares or
pay an amount in accordance with this clawback provision, any such shares or cash must be transferred or paid (as directed by Unilever) within 30 days of the notification. 

To avoid doubt, in exercising its powers under these malus and clawback provisions, the Committee may, in its discretion, apply different treatments to:
(i) different employees and/or (ii) different remuneration, and may apply such different treatment in combination. These provisions can apply even if you are not responsible for the event in question, or if it happened before the vesting
or grant of your performance-related remuneration. 
 Personal shareholding requirement. In your role as an Executive Director you are required
to demonstrate a significant personal shareholding commitment to Unilever, in line with our Personal Shareholding Requirement Standard. Just as a reminder, you are required to retain all shares vesting from any share awards made since
your appointment until your personal shareholding requirement of at least five times your fixed pay has been met. I’m pleased to confirm that you currently satisfy the Personal Shareholding Requirement. You need to continue holding shares after
your employment ends (100% of the minimum shareholding requirement for 12 months post cessation, and 50% for 24 months post cessation). 
 Next
steps. If you have any questions about the above (or the Reward Framework/ Remuneration Policy generally), please don’t hesitate to contact me via margot.fransen@unilever.com / +31 622205291. 

Please then reply “AGREED” to my covering email to confirm that you agree to the terms and conditions of this letter, including the operation of clawback and
malus, and that you have read the relevant award documentation, plan rules and related policies/standards (as amended or replaced from time to time) which set out the clawback and malus provisions in more detail, and that you agree to be bound by
their terms. In particular, you consent to any repayment, withholding or deduction made in accordance with such provisions (otherwise such agreement will be deemed to have been given as appropriate for Unilever to operate these arrangements on the
above basis). 

 With kind regards, 
 Margot
Fransen 
 Chief Counsel Executive Compensation & Employment 

					
	  
  
  

 
  
 Private &
Confidential
 Graeme Pitkethly
 graeme.pitkethly@unilever.com
	  	 

  
	  	

  
 20 February 2020 

Dear Graeme, 
 Your reward package in respect of 2020 

This letter outlines your reward package for 2020 authorised by the Compensation Committee (the “Committee”). Any defined terms used have the meaning set out
in your service agreement (your “Agreement”) with Unilever PLC and Unilever NV (collectively referred to here as “Unilever”) if not otherwise defined here. 

 

			
	REWARD PACKAGE FOR 2020
		
	Fixed pay:	  	 1,135,960 EUR p.a.
  

With effect from 1 January 2020, fixed pay has been reviewed by the Compensation Committee and has increased by 3%. Your fixed pay is denominated in Euros (and
payable in equal monthly instalments).

		
	Discretionary annual bonus:	  	 2019: Discretionary annual bonus outcome: 1,085,228 EUR
  

This is your annual bonus award in respect of 2019. It represents your annual bonus target (120% of your fixed pay) multiplied by Unilever’s 2019 performance ratio
of 82%. Any cash portion of your bonus payable to you (less MCIP election – see below) will be paid in the March 2020 payroll. For further details regarding your bonus outcome, please refer to the Directors’ Remuneration Report (DRR) of
the 2019 Annual Report and Accounts (ARA).
  
 2020: Discretionary annual bonus target: 120% of
fixed pay
  
 Your discretionary annual bonus target for 2020 will remain as set out above.
The maximum discretionary annual bonus is 180% of fixed pay (150% of target bonus). Performance measures are as set out in the DRR. Details of the performance targets approved by the Committee will be communicated to you separately.

		
	MCIP:	  	 2020: You have chosen to invest 727,103 EUR in the MCIP 2020-2023
  

You have opted to invest the maximum 67% (727,103 EUR) of your 2019 discretionary annual bonus award in Unilever shares (“investment shares”) under the
Unilever Share Plan 2017 (the “Plan”). Each of these investment shares will become eligible for 1.5 match shares which will vest between 0-200% four years from the award date in line with the rules
of the Plan and performance against the measures/targets set out in the DRR.
 An additional one-year holding period will apply
after the four-year vesting period.

		
	Benefits:	  	 Unilever will continue to provide the following benefits on the same basis as currently:

 
 •  medical cover for you and your
family via the Allianz Worldwide Care International Healthcare Plan;
  

•  life insurance cover at three times your fixed pay (any additional cover elected by you will be for
your own account); and
  
 •  actual and
reasonable costs of tax return preparation in respect of total Unilever earnings via Unilever’s designated tax advisor.

 Please note that, whilst performance measures and target ranges have been approved by the Committee,
in-flight performance measures and target ranges may be adjusted if and to the extent deemed appropriate by the Committee (in which case we will notify you separately in writing). 

In addition, all payments/awards set out above are gross, and subject to: any necessary deductions for tax/social security; the malus/clawback provisions set out below;
the terms and conditions of your Agreement (which are 

 
unchanged save as set out in this letter), relevant award documentation, plan rules and related policies/standards (as amended or replaced from time to time). 

Malus and clawback. All performance-related remuneration awarded to you, including but not limited to any annual bonus and GSIP/ MCIP awards, is
subject to malus and clawback as follows: 
 Malus: If the Committee considers that there is: 

 

	 	•	 	 a significant downward restatement of the financial results of Unilever; 

 

	 	•	 	 reasonable evidence of gross misconduct or gross negligence by you; 

 

	 	•	 	 reasonable evidence of material breach by you of Unilever’s Code of Business Principles or Code Policies;

  

	 	•	 	 breach of restrictive covenants by which the individual has agreed to be bound; and/or 

 

	 	•	 	 reasonable evidence of conduct by you that results in significant losses or reputational damage to Unilever

 it may, in its discretion, at any time prior to your performance-related remuneration vesting or being paid, decide that some or all of your
performance-related remuneration (which is subject to this malus and clawback provision) will be reduced, lapse or be subject to additional conditions, or the delivery of your performance-related remuneration will be delayed. 

Clawback: If the Committee considers that there is a significant downward restatement of our financial results it may, in its discretion, within two years of
your performance-related remuneration (which, for the avoidance of doubt) includes vested awards under the GSIP and MCIP) vesting or being paid: 
  

	 	•	 	 require you to repay to Unilever (or as Unilever directs) an amount equal to the
after-tax value of some or all of any cash bonus you were paid (as determined by the Committee); and/or 

  

	 	•	 	 require you to transfer to Unilever (or as Unilever directs) for nil consideration, some or all of the after-tax number of Unilever shares which have previously vested, or pay to Unilever (or as Unilever directs) an amount equal to the value of those shares (as determined by the Committee); and/or

  

	 	•	 	 require Unilever to withhold from, or offset against, any other remuneration to which you may be or become entitled in
connection with your employment such an amount as the Committee considers appropriate. 

 Where you are notified that you must transfer shares or
pay an amount in accordance with this clawback provision, any such shares or cash must be transferred or paid (as directed by Unilever) within 30 days of the notification. 

To avoid doubt, in exercising its powers under these malus and clawback provisions, the Committee may, in its discretion, apply different treatments to:
(i) different employees and/or (ii) different remuneration, and may apply such different treatment in combination. These provisions can apply even if you are not responsible for the event in question, or if it happened before the vesting
or grant of your performance-related remuneration. 
 Personal shareholding requirement. As you know, in your role as an Executive Director you
are required to demonstrate a significant personal shareholding commitment to Unilever, in line with our Personal Shareholding Requirement Standard. Just as a reminder, you are required to retain all shares vesting from any share awards made
since your appointment until your personal shareholding requirement of at least four times your fixed pay has been met and maintained thereafter. I’m pleased to confirm that you currently satisfy the Personal Shareholding Requirement. You need
to continue holding shares after your employment ends (100% of the minimum shareholding requirement for 12 months post cessation, and 50% for 24 months post cessation). 

Next steps. If you have any questions about the above (or the Reward Framework / Remuneration Policy generally), please don’t hesitate to
contact me via margot.fransen@unilever.com / +31 622205291. 
 Please then reply “AGREED” to my covering email to confirm that you agree to the terms
and conditions of this letter, including the operation of clawback and malus, and that you have read the relevant award documentation, plan rules and related policies/standards (as amended or replaced from time to time) which set out the clawback
and malus provisions in more detail, and that you agree to be bound by their terms. In particular, you consent to any repayment, withholding or deduction made in accordance with such provisions (otherwise such agreement will be deemed to have been
given as appropriate for Unilever to operate these arrangements on the above basis). 

 With kind regards, 
 Margot
Fransen 
 Chief Counsel Executive Compensation & EmploymentExhibit
4.6

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT

TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

The
following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws,
each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part.
This summary does not purport to be complete and is qualified in its entirety by the full text of our aforementioned certificate
of incorporation and bylaws and by applicable law.

 

Our
authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares
of Preferred Stock, par value $0.0001 per share.

 

The
additional shares of our authorized stock available for issuance might be issued at times and under circumstances so as to have
a dilutive effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board
of directors to issue additional shares of stock could enhance the board’s ability to negotiate on behalf of the stockholders
in a takeover situation but could also be used by the board to make a change-in-control more difficult, thereby denying stockholders
the potential to sell their shares at a premium and entrenching current management. The following description is a summary of
the material provisions of our capital stock. You should refer to our amended and restated certificate of incorporation and by-laws,
both of which are on file with the SEC as exhibits to previous SEC filings, for additional information. The summary below is qualified
by provisions of applicable law.

 

Common
Stock

 

Voting.
The holders of our common stock are entitled to one vote for each share held of record on all matters on which the holders are
entitled to vote (or consent to).

 

Dividends.
The holders of our common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of
directors out of funds legally available therefor and after provision is made for each class of capital stock having preference
over the common stock (including the common stock).

 

Liquidation
Rights. In the event of our liquidation, dissolution or winding-up, the holders of our common stock are entitled to share,
ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each
class of capital stock having preference over the common stock (including the common stock).

 

Conversion
Rights. The holders of our common stock have no conversion rights.

 

Preemptive
and Similar Rights. The holders of our common stock have no preemptive or similar rights.

 

Redemption/Put
Rights. There are no redemption or sinking fund provisions applicable to the common stock. All of the outstanding shares of
our common stock are fully-paid and nonassessable.

 

Transfer
Agent and Registrar. The transfer agent and registrar for our common stock is VStock Transfer, LLC.

 

Preferred
Stock

 

We
are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share, (of which 1,600,000 shares have
been designated as Series A Preferred Stock) with such designations, rights, and preferences as may be determined from time to
time by our board of directors. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred
stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights
of the holders of our common stock. The issuance of preferred stock could have the effect of restricting dividends on our common
stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying or preventing
a change in control of our company, all without further action by our stockholders.

 

    	 	 	 

    	 

    

 

Our
board of directors has the authority, within the limitations and restrictions prescribed by law and without stockholder approval,
to provide by resolution for the issuance of shares of preferred stock, and to fix the rights, preferences, privileges and restrictions
thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference and the number
of shares constituting any series of the designation of such series, by delivering an appropriate certificate of amendment to
our amended and restated certificate of incorporation to the Delaware Secretary of State pursuant to the Delaware General Corporation
Law (the “DGCL”). The issuance of preferred stock could have the effect of decreasing the market price of the common
stock, impeding or delaying a possible takeover and adversely affecting the voting and other rights of the holders of our common
stock.

 

If
we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the
prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock
with the SEC. To the extent required, this description will include:

 

	●	the
    title and stated value;
	●	the
    number of shares offered, the liquidation preference per share and the purchase price;
	●	the
    dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
	●	whether
    dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
	●	the
    procedures for any auction and remarketing, if any;
	●	the
    provisions for a sinking fund, if any;
	●	the
    provisions for redemption, if applicable;
	●	any
    listing of the preferred stock on any securities exchange or market;
	●	whether
    the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be
    calculated) and conversion period;
	●	whether
    the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated)
    and exchange period;
	●	voting
    rights, if any, of the preferred stock;
	●	a
    discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock;
	●	the
    relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or
    winding up of the affairs of Matinas; and
	●	any
    material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series
    of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of Matinas.

 

Transfer
Agent and Registrar for Preferred Stock. The transfer agent and registrar for any series or class of preferred stock will
be set forth in each applicable prospectus supplement.

 

Series
A Preferred Stock

 

Our
board of directors created out of the authorized and unissued shares of our preferred stock, a series of preferred stock comprised
of 1,600,000 shares of Series A Preferred Stock. All shares of Series A Preferred Stock have been automatically converted pursuant
to the terms of the certificate of designation. 

 

Series
B Preferred Stock

 

Our
board of directors created out of the authorized and unissued shares of our preferred stock, a series of preferred stock comprised
of 15,000 shares
of Series B Preferred Stock. Each share of Series B Preferred have a stated value of $1,000 per share.

 

Rank.
The Series B Preferred rank

 

	●	junior
    to our Series A Preferred Stock and any class or series of our capital stock hereafter created specifically ranking by its
    terms senior to the Series B Preferred;
	●	senior
    to all of our common stock;

 

    	 	 	 

    	 

    

 

	●	senior
    to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series B Preferred;
    and
	●	on
    a parity with any class or series of our capital stock hereafter created specifically ranking by its terms on a parity with
    the Series B Preferred.

 

in
each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily.

 

Dividends.
Holders of the Series B Preferred are entitled to receive dividends payable as follows: (i) a number of shares of common stock
equal to 10% of the shares of common stock underlying the Series B Preferred then held by such holder on the 12 month anniversary
of the COD Effective Date, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series
B Preferred then held by such holder on the 24-month anniversary of the COD Effective Date and (iii) a number of shares of common
stock equal to 20% of the shares of common stock underlying the Series B Preferred then held by such holder on the 36-month anniversary
of the COD Effective Date. In the event a purchaser in this offering no longer holds Series B Preferred as of the 12-month anniversary,
the 24-month anniversary or the 36 month anniversary, such purchaser will not be entitled to receive any dividends on such anniversary
date.

 

Optional
Conversion. Each share of Series B Preferred is convertible into shares of our common stock at any time at the option of the
holder at a conversion price $0.50 per share (subject to adjustment for reverse splits, stock combinations and similar changes
as provided in the certificate of designation). Holders of Series B Preferred are prohibited from converting Series B Preferred
into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially
own more than 4.99% (or upon the election by a holder prior to the issuance of any shares of Series B Preferred, 9.99%) of the
total number of shares of our common stock then issued and outstanding. Dividends will not accrue and will not be paid following
optional conversion.

 

Automatic
Conversion. Each share of our Series B Preferred shall automatically convert into 2,000 shares of our common stock at a conversion
price of $0.50 per share upon the earlier of (i) the first FDA approval of one of our product candidates, (ii) the 36-month anniversary
of the COD Effective Date or (iii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series
B Preferred. In the event the Series B Preferred automatically converts into common stock prior to the 36 month anniversary of
the COD Effective Date, the holder on the date of such conversion shall also be entitled to receive those dividends which would
have been payable after the conversion date, as if the shares of Series B Preferred had remained unconverted and outstanding through
the 36 month anniversary of the COD Effective Date. Such dividend amount shall be payable as set forth above in shares of common
stock upon such automatic conversion.

 

Liquidation
Preference. In the event of a liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the
proceeds and/or assets of our company remaining after giving effect to such transaction, and the payment of all of our debts and
liabilities will be distributed first to the holders of our Series A Preferred Stock and thereafter to the holders of Series B
Preferred and then to stockholders of common stock (including the holders of our Series A Preferred Stock and Series B Preferred
on an “as converted” basis) on a pro rata basis.

 

Voting
Rights. Except as provided in the Certificate of Designation of the Series B Preferred or as otherwise required by law, the
holders of Series B Preferred will have no voting rights. However, we may not, without the consent of holders of a majority of
the outstanding shares of Series B Preferred, alter or change adversely the powers, preferences or rights given to the Series
B Preferred, increase the number of authorized shares of Series B Preferred, or enter into any agreement with respect to the foregoing.

 

Redemption.
We will be not obligated to redeem or repurchase any shares of Series B Preferred. Shares of Series B Preferred will not otherwise
be entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.

 

Transfer
Agent, Registrar and Dividend Disbursing Agent. The transfer agent, registrar and dividend disbursing agent for our Series
B preferred stock is VStock Transfer, LLC.

 

    	 	 	 

    	 

    

 

Anti-takeover
Effects of Delaware Law and of our Amended and Restated Certificate of Incorporation

 

The
following paragraphs summarize certain provisions of the DGCL and our amended and restated certificate of incorporation that may
have the effect of discouraging an acquisition of Matinas. The summary does not purport to be complete and is subject to and qualified
in its entirety by reference to the DGCL and our amended and restated certificate of incorporation and by-laws, copies of which
are on file with the SEC. Please refer to “Additional Information” below for directions on obtaining these documents.

 

Section
203 of the Delaware General Corporation Law

 

We
are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an
interested stockholder, with the following exceptions:

 

	●	before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted
    in the stockholder becoming an interested stockholder;
	●	upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes
    of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those
    shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants
    do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
    exchange offer; or
	●	on
    or after such date, the business combination is approved by the board of directors and authorized at an annual or special
    meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
    stock that is not owned by the interested stockholder.

 

In
general, Section 203 defines business combination to include the following:

 

	●	any
    merger or consolidation involving the corporation and the interested stockholder;
	●	any
    sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;
	●	subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;
	●	any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
    or series of the corporation beneficially owned by the interested stockholder; or
	●	the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits
    by or through the corporation.

 

In
general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s
affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder
status did own, 15% or more of the outstanding voting stock of the corporation.

 

Certificate
of Incorporation and Bylaws

 

Our
certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals
or tender offers or delaying or preventing a change of control of our company. These provisions are as follows: 

 

	●	they
    provide that special meetings of stockholders may be called only by the board of directors, President or our Chairman of the
    board of directors, or at the request in writing by stockholders of record owning at least fifty (50%) percent of the issued
    and outstanding voting shares of common stock;
	●	they
    do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority stockholder
    holding a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative
    voting may have the effect of limiting the ability of minority stockholders to effect changes in our board of directors; and
	●	they
    allow us to issue “blank check” preferred stock, the terms of which may be established and shares of which may
    be issued without stockholder approval.

 

    	 	 	 

    	 

    

 

Potential
Effects of Authorized but Unissued Stock

 

We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these
additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate
corporate acquisitions or payment as a dividend on the capital stock.

 

The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons
friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party
attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity
of our management. In addition, the board of directors has the discretion to determine designations, rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences
of each series of preferred stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth
in our amended and restated certificate of incorporation. The purpose of authorizing the board of directors to issue preferred
stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a
stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with
possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party
to acquire, or could discourage a third-party from acquiring, a majority of our outstanding voting stock.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]